Key Takeaways
- United Therapeutics (UTHR) shares climbed approximately 13% following a favorable Delaware federal court decision in a patent infringement lawsuit.
- The ruling determined that Liquidia violated two specific patent claims related to inhaled treprostinil therapies.
- Liquidia (LQDA) experienced a dramatic decline, with shares plummeting more than 50% following the court’s decision.
- The court has ordered both pharmaceutical companies to present proposed remedies within seven days.
- UTHR shares are currently trading close to their 52-week peak and have gained roughly 10% year-to-date.
Shares of United Therapeutics (NASDAQ: UTHR) skyrocketed 13% on Wednesday following a federal court ruling that sided with the biotechnology company in an extended patent litigation battle. Trading reached approximately $543.86 per share, approaching the 52-week peak of $596.76 recorded in May 2026.
United Therapeutics Corporation, UTHR
The Delaware District Court determined that competitor Liquidia Corporation violated two specific patent claims owned by United Therapeutics. These claims pertain to the treatment of pulmonary hypertension with interstitial lung disease through inhaled treprostinil administration, including dry powder delivery systems.
In stark contrast, Liquidia’s stock price collapsed following the announcement, declining more than 50% during the trading session.
Details of the Court’s Ruling
The federal court concluded that claims 1 and 14 of U.S. Patent No. 11,826,327 were both valid and violated by Liquidia’s Yutrepia inhalation powder product. However, the court invalidated four additional claims that United Therapeutics had presented during litigation.
The court has given both pharmaceutical companies seven days to present proposed legal remedies. United Therapeutics has already requested injunctive relief through its post-trial submissions. Such an injunction could significantly restrict Liquidia’s ability to commercialize Yutrepia moving forward.
The FDA approved Yutrepia in 2025 for treating both pulmonary arterial hypertension and PH-ILD. United Therapeutics initiated this legal action under provisions of the Hatch-Waxman Act, which establishes the framework for patent disputes involving branded and generic pharmaceutical manufacturers.
Liquidia’s Position and Next Steps
Roger Jeffs, CEO of Liquidia, expressed disagreement with the court’s findings regarding claims 1 and 14. He confirmed that the company will pursue an appellate challenge to the decision.
Jeffs further indicated that Liquidia plans to file a supplemental submission to Yutrepia’s New Drug Application. This action would aim to completely eliminate the PH-ILD indication from the medication’s approved labeling.
Liquidia acknowledged it cannot currently quantify the financial consequences of this ruling. The company cited numerous uncertain factors, including the appeals timeline and additional court proceedings that remain pending.
Potential outcomes span from a more limited label for Yutrepia to extensive restrictions on the product’s market accessibility.
This isn’t the only significant price movement for United Therapeutics stock in recent weeks. Just six days prior, shares declined 4% after Goldman Sachs analyst Andrea Newkirk initiated coverage with a Sell recommendation.
Large single-day movements are unusual for United Therapeutics shares. The stock has experienced daily price swings exceeding 5% only five times during the past twelve months, making this week’s surge particularly notable.
Year-to-date, the stock has appreciated approximately 10%. An investor who allocated $1,000 to United Therapeutics five years ago would currently hold a position valued at around $2,947.
The litigation now advances to its remedies phase, with both companies required to submit their proposed solutions within the coming week.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
